AKT1 and invasive breast carcinoma: Thus, stimulation with CXCL16 could suppress apoptotic signaling, facilitate overriding cell cycle checkpoints, promote EMT, and ultimately confer a survival benefit to BrCa cells via its effects on Akt, NFkB stability and processing, BRCA, and the SAPK/JNK pathway.